Micro-Botox: a new shot at smaller pores?
NCT ID NCT07526870
First seen May 04, 2026
Summary
This pilot study tested whether tiny injections of botulinum toxin (micro-Botox) can reduce facial oiliness and shrink enlarged pores. Thirty adults aged 18 to 35 received the treatment around their eyes. Researchers measured oil production and patient satisfaction after 6 weeks to see if the approach is safe and effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FACIAL AGING are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
✔ Instituto de Oftalmología Fundación Conde de Valenciana IAP
Mexico City, Mexico
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Botulinum toxin type A (Dysport®) in microdoses
What this could lead to
If it works, this could offer a minimally invasive option for reducing facial oiliness and pore size with fewer side effects than standard treatments.
What could go wrong
This is a small pilot study with only 30 people and no comparison group. Results may not apply to everyone, and long-term safety is unknown.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.